CV Sciences (CVSI) is a CBD and hemp company trading on the OTC. The stock is currently priced at $0.0083 with a market capitalization of $1.9M and trailing twelve-month revenue of $12.7M. The company reports a gross margin of 49.1%. View SEC filings ↗
Market Cap
$1.9M
Volume
576.9K
Prev Close
$0.0093
52W High
$0.10
52W Low
$0.0071
P/S Ratio
0.15
Shares Out
225.8M
Revenue
$12.7M
Gross Margin
49.1%
Cash
$266.0K
CVSI Price Chart
Latest Quarterly Results
In Q2 2026, CV Sciences reported revenue of $3.0M, down 17.5% from Q2 2025. Gross margin was 48.6%. The net loss was $775.0K. The company ended the quarter with $266.0K in cash and $18.0K of debt.
| CVSI | Q2 2026 | YoY |
|---|---|---|
| Revenue | $3.0M | -17.5% |
| Gross margin | 48.6% | -2.4 pts |
| Net income | -$775.0K | — |
| Operating cash flow | $20.0K | -93.0% |
| Cash & equivalents | $266.0K | -70.0% |
| Total debt | $18.0K | -98.8% |
Source: SEC filings, in USD; quarters are calendar quarters of the period end. Latest filing: 10-Q, filed Aug 13, 2026 ↗. Next report expected around Nov 16, 2026 (estimate).
Trading Data
Valuation Metrics
Financial Highlights
View Full FinancialsQuarterly Revenue
Reported quarterly revenue (SEC filings)
TTM: $12.7M
CVSI Key Takeaways
- CV Sciences (CVSI) trades at $0.0083 with a market cap of $1.9M, ranking #66 among 71 cannabis stocks.
- Trailing twelve-month revenue is $12.7M, declining -14.90% year-over-year.
- Gross margin stands at 49.1% — strong margin profile for a cannabis company.
- Balance sheet shows $266.0K cash against $18.0K debt — net cash positive.
- Price-to-Sales ratio of 0.15x — below sector median, potentially undervalued.
- Ranked #6 by market cap in the CBD sector. Trades on the OTC exchange.
CVSI Stock Analysis
CV Sciences (CVSI) is a CBD and hemp company listed on the OTC exchange, headquartered in the United States. With a current share price of $0.0083 and a market capitalization of $1.9M, CVSI ranks #66 out of 71 publicly traded cannabis stocks tracked on Cannabismarketcap.
From a fundamental perspective, CV Sciences reports trailing twelve-month revenue of $12.7M, representing a decline of -14.90% year-over-year. The company maintains a gross margin of 49.1%, which places it among the stronger operators in the cannabis space. At a price-to-sales multiple of 0.15x, the stock appears attractively valued relative to its revenue base.
The company's balance sheet shows $266.0K in cash and equivalents against $18.0K in total debt, resulting in a healthy net cash position of $248.0K. At the current burn rate, estimated cash runway is approximately 6 months. Investors looking for a deeper dive can explore CVSI's full financial statements including quarterly breakdowns and balance sheet history.
CVSI currently trades within a 52-week range of $0.0071 to $0.10. Average daily trading volume stands at 576.9K shares.
Corporate Information
Share Structure
CVSI Price History
Investment Snapshot
Programmatic analysis based on available financial data. Not investment advice.
Ranked #66 of 71 by market cap ($1.9M). Sector median: $32.9M.
Net cash: $248.0K ($266.0K cash, $18.0K debt). Gross margin at 49.1%.
Revenue growth at -14.9% YoY. Sector median: +1.6%.
P/S ratio of 0.15x vs sector median of 0.71x. Potentially undervalued.
Cannabis Industry Context
Cannabis Industry Overview
The hemp-derived CBD market emerged as a mainstream consumer category following the passage of the 2018 Farm Bill, which removed hemp (defined as cannabis containing less than 0.3% THC) from the Controlled Substances Act. This legislative milestone enabled the legal cultivation, processing, and interstate commerce of hemp-derived products, catalyzing a wave of CBD brands targeting the wellness, skincare, pet care, and functional food markets. However, the FDA has not established a comprehensive regulatory framework for CBD in food and dietary supplements, creating uncertainty that has limited major retail distribution and institutional investment. The CBD market has experienced significant price compression as supply overwhelmed demand, and many early entrants struggled to achieve profitability. Companies that have differentiated through brand strength, third-party testing and transparency, unique formulations, or established retail partnerships have fared better. The sector continues to await clarity from the FDA on permissible product categories and health claims, which could significantly expand the addressable market if and when comprehensive regulations are finalized.
CV Sciences in the CBD / Hemp Landscape
CV Sciences (CVSI) currently ranks #6 out of 7 publicly traded cbd / hemp companies by market capitalization, with a market cap of $1.9M. The company reports trailing-twelve-month revenue of $12.7M, placing it below the sector median of $20.9M. The cbd / hemp sector comprises 7 tracked companies, reflecting the focused competitive landscape within this segment of the cannabis industry.
The top companies in the cbd / hemp sector by market capitalization are Charlotte's Web Holdings (CWBHF) at $64.6M, PharmaCielo (PCLOF) at $7.5M, and cbdMD Inc (YCBD) at $4.2M. CV Sciences competes within this group for market share, investor attention, and operational scale as the sector continues to mature.
Key Metrics at a Glance
Regulatory & Risk Considerations
All cannabis investors should be aware that federal legalization status in the United States remains uncertain. While cannabis is legal for medical use in the majority of US states and for adult use in a growing number of jurisdictions, it remains classified as a Schedule I controlled substance at the federal level. This creates material legal, financial, and operational risks across the industry. CBD companies like CV Sciences operate in a regulatory gray area created by the gap between the 2018 Farm Bill's legalization of hemp and the FDA's incomplete regulatory framework for CBD in food, beverages, and dietary supplements. This ambiguity has deterred major retailers and institutional investors, limiting distribution and capital access for CBD brands.
Additional risks include state-by-state variations in CBD product regulations, inconsistent enforcement of THC content limits, and consumer confusion about product quality and efficacy. The potential entry of major CPG companies into the CBD space — which may accelerate once FDA regulations are finalized — represents both an opportunity (market expansion and legitimacy) and a threat (intensified competition and marketing spend requirements) for existing CBD-focused companies.
Compare CVSI With Peers
Related CBD Stocks
Frequently Asked Questions
What is CV Sciences's (CVSI) stock price today?▼
CV Sciences (CVSI) stock is currently trading at $0.0083 per share on the OTC exchange. This represents a daily decline of -10.80% ($0.0010) from the previous closing price of $0.0093. Over the past 52 weeks, CVSI has traded between a low of $0.0071 and a high of $0.10, placing the current price at approximately -92% from its annual high. The stock has a market capitalization of $1.9M, making it a notable cannabis companies tracked by Cannabismarketcap. CV Sciences operates in the CBD sector, serving the broader cannabis industry.
What is CV Sciences's market capitalization?▼
CV Sciences (CVSI) has a current market capitalization of $1.9M, calculated by multiplying its 225.8M shares outstanding by the current stock price of $0.0083. Market capitalization is a key measure of a company's total equity value as perceived by the public market, and it places CV Sciences among the small-cap cannabis companies tracked on Cannabismarketcap. For context, the enterprise value (market cap plus debt minus cash) stands at $1.6M, which accounts for the company's balance sheet structure. Investors often use market cap alongside revenue and profitability metrics to assess relative valuation within the cannabis sector.
Is CV Sciences profitable?▼
CV Sciences (CVSI) currently reports a gross margin of 49.1%, which means the company retains 49.1 cents of every revenue dollar after direct costs of goods sold. On trailing twelve month revenue of $12.7M, this translates to an estimated gross profit of approximately $6.3M. Profitability is a critical factor in the cannabis industry, where many companies are still investing heavily in growth and regulatory compliance. Investors should review the full income statement, cash flow trends, and operating expense breakdown on Cannabismarketcap for a complete picture of CV Sciences's financial health.
What is CV Sciences's annual revenue?▼
CV Sciences (CVSI) reports trailing twelve month (TTM) revenue of $12.7M, reflecting the total sales generated by the company over the most recent four quarters. Revenue has changed -14.90% year-over-year, reflecting a contraction in top-line performance relative to the prior period. The current price-to-sales ratio is 0.15x, which means investors are paying $0.15 for every $1 of annual revenue — a relatively low valuation in the context of the cannabis sector. Revenue is one of the most closely watched metrics for cannabis companies, as many are still scaling operations in a rapidly evolving regulatory environment. View the full income statement and quarterly revenue breakdown on Cannabismarketcap for detailed trend analysis.
What exchange is CVSI listed on?▼
CV Sciences trades under the ticker symbol CVSI on the OTC exchange, and the stock is denominated in US dollars (USD). Shares can typically be purchased through most standard brokerage accounts, though some brokers may charge additional fees for OTC-listed securities. The stock sees average daily trading volume of approximately 576.9K shares, which is an important consideration for liquidity and the ability to enter or exit positions without significant price impact.
What is CV Sciences's gross margin?▼
CV Sciences (CVSI) has a gross margin of 49.1%, which represents the percentage of revenue the company retains after paying for the direct cost of goods sold. On trailing twelve month revenue of $12.7M, this translates to an estimated gross profit of approximately $6.3M. Gross margin is a critical profitability indicator in the cannabis industry, where companies face unique cost pressures from regulatory compliance, testing requirements, and the tax burden of IRC Section 280E (which prevents cannabis companies from deducting standard business expenses). A moderate gross margin like CV Sciences's suggests the company has pricing power and operational efficiency relative to peers.
What is CVSI's 52-week trading range?▼
CV Sciences (CVSI) has traded between a 52-week low of $0.0071 and a 52-week high of $0.10, with the current price of $0.0083 sitting approximately -92% from the annual high. This range represents a spread of $0.0929 (1308% from low to high), which reflects the volatility the stock has experienced over the past year. The 52-week range is a commonly used technical indicator that helps investors understand whether a stock is trading near the top or bottom of its recent range, and it can inform decisions about entry and exit points. Cannabis stocks in general tend to exhibit higher volatility than broader market indices due to evolving regulations and market sentiment.
What is CV Sciences's cash position and debt level?▼
CV Sciences (CVSI) holds $266.0K in cash and equivalents on its balance sheet, set against $18.0K in total debt. This gives the company a net cash position of $248.0K. At the current rate of cash usage, the company has an estimated cash runway of approximately 6 months before needing additional financing, which could come from operations, debt, or equity issuance. Balance sheet strength is especially important in the cannabis industry, where companies often face limited access to traditional banking and capital markets. Investors should track these metrics over time on Cannabismarketcap to identify trends in cash consumption and debt management.
How many shares outstanding does CV Sciences have?▼
CV Sciences (CVSI) currently has 225.8M shares outstanding, which when multiplied by the current stock price of $0.0083 gives the company its market capitalization of $1.9M. Share count is important because all per-share metrics (earnings per share, book value per share, etc.) are directly impacted by changes in shares outstanding. Cannabis companies frequently issue new shares to raise capital, so monitoring dilution trends on Cannabismarketcap is recommended for long-term investors.
Embed CVSI Widget
Add the CVSI price widget to your website or blog:
<iframe src="https://cannabismarketcap.io/embed/cvsi" width="320" height="180" frameborder="0" style="border-radius:8px;border:1px solid #415a77"></iframe>Data updates every 2 minutes. Free for non-commercial use.
Disclaimer
The information on this page is provided for informational purposes only and does not constitute financial advice, investment recommendations, or an offer to buy or sell securities. Cannabismarketcap is not a registered broker-dealer or investment advisor. All data, including stock prices, market capitalizations, financial metrics, and analysis for CV Sciences (CVSI), is provided “as is” without warranty of any kind. Past performance does not guarantee future results. Cannabis stocks are highly volatile and carry significant risk, including the potential for total loss of investment. Marijuana remains illegal under federal law in the United States. Always conduct your own due diligence and consult a qualified financial advisor before making investment decisions. Data may be delayed or inaccurate. See our terms of service and privacy policy for more information.